Abstract:In the past decade, a growing body of evidence has shown that HBsAg quantification (qHBsAg) not only is a useful marker for monitoring natural history of treatment-naïve Chronic HBV Infection (CHB) but can also predict clinical and treatment outcomes [1]. While, other study indicated that, being used alone, qHBsAg is not a suitable marker for evaluating hepatitis activity and distinguishing between cases of HBeAg-negative CHB and inactive HBV carrier state [2]. In our study, we showed that qHBsAg had high predictive value for discrimination of immune tolerance (IT) and Immune Clearance (IC) phase, and it had moderate predictive value for differentiation of low replication (LR) phase and HBeAg Negative Hepatitis (ENH) [3]. While, role of HBeAg quantification (qHBeAg) in natural phases of HBV infection has not been attracted more attention up to now. We found that in HBeAg positive phase of treatment-naïve CHB, qHBsAg and qHBeAg correlated positively (P<0.0001), and both had strong negative correlation with grade of liver inflammation (G) (P<0.0001) and Fibrosis stage (F) (P<0.0001) (unpublished data). Thus, we might speculate that qHBeAg can either be used as a marker of natural phases of HBV infection in HBeAg positive patients. Indeed, we demonstrated that qHBeAg had moderate predictive value for discriminating IT and IC phase [3]. And qHBsAg and qHBeAg had moderate predictive value for F1, F2 and F3 and for G2 and G3 in treatment-naïve HBeAg positive CHB (unpublished data). In recent years, HBcAb quantification (qHBcAb) has been indicated to be associated with HBV infection induced hepatitis [4]. We also suggested that qHBcAb are higher in IC and ENH phases than in IT and LR phases. And qHBcAb correlated positively with grade of liver inflammation. Whereas, the qHBcAb has low divisional value for the intermediate grades of inflammation (unpublished data). Next, we will determine whether qHBcAb is different with liver injury of different etiologies in HBV infection, including HBV infection merged with non-alcoholic fatty liver disease or combined with drug induced liver injury. In all, qHBsAg had high and qHBeAg had moderate predictive value for discrimination of IT and IC phase. And both had moderate predictive value for diagnosis of mild to severe liver fibrosis in treatment-naïve HBeAg positive CHB. Both qHBsAg and qHBcAb had moderate predictive value for differentiation of LR and ENH phase.

Serum Proteomics Analysis and Comparisons Using Itraq in the Progression of Hepatitis B

iTRAQ-based proteomic analysis of hepatic tissues from patients with hepatitis B virus-induced acute-on-chronic liver failure.

Serum Biomarkers of Hepatitis B Virus Infected Liver Inflammation: A Proteomic Study

Circulating Proteomic Panels For Diagnosis And Risk Stratification Of Acute-On-Chronic Liver Failure In Patients With Viral Hepatitis B

Correlation between plasma amino acid profiles and the various stages of hepatitis B infection

Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B

The primary research on different expressing of plasma proteomics in chronic severe hepatitis B

Profiling serum low molecular weight proteins in patients with chronic severe hepatitis

Search for Potential Serum Biomarkers in Hepatocellular Carcinoma Using iTRAQ-Coupled LC-MS/MS

Serum Peptide Profiles During Progression of Chronic Hepatitis B Virus Infection to Liver Failure

[Plasma Proteome Analysis of Chronic Hepatitis B Patients with Different Stages of Liver Fibrosis].

A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry.

[Proteomic Analysis of Hepatitis B Virus-Infected Human Liver Tissues].

Analysis of Differentially Expressed Proteins Involved in Autoimmune Cirrhosis and Normal Serum by Itraq Proteomics

Analysis of serum immune parameters of patients with chronic hepatitis B with different levels of hepatitis B viral load

Serum Cytokine Analysis Reveals Predictors of Progression from Chronic Hepatitis B to Liver Cirrhosis

Serum Proteomic MRM Identify Peptide Ions of Transferrin As New Fibrosis Markers in Chronic Hepatitis B.

Proteome Differences Between Hepatitis B Virus Genotype-B- and Genotype-C-Induced Hepatocellular Carcinoma Revealed by Itraq-Based Quantitative Proteomics.

4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients

Serum protein expression patterns in detecting a new viral protein in HBeAg-negative chronic hepatitis B.

Role of Serum Hepatitis B Virus Marker Quantitation to Differentiate Natural History